<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-94 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-94</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-94</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-58b0367d5d210545ae81e23f057f729ea42e5668</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/58b0367d5d210545ae81e23f057f729ea42e5668" target="_blank">Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.</a></p>
                <p><strong>Paper Venue:</strong> Lung Cancer</p>
                <p><strong>Paper TL;DR:</strong> As the search for better targeted therapies for patients with HER2-mutant lung cancers, chemotherapy remains an important component of care.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e94.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e94.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 (ERBB2) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Human epidermal growth factor receptor 2 (ERBB2/HER2) tyrosine kinase domain mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic activating mutations in ERBB2 (HER2) occur in lung adenocarcinomas and act as oncogenic drivers by activating downstream PI3K-AKT and MEK-ERK signaling; these are rare (few percent) but recurrent and heterogeneous (insertions and point mutations).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 (HER2) somatic mutations (various)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations and in-frame insertions (kinase and extracellular domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK → downstream PI3K-AKT and MEK-ERK pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>2-3% of lung cancers (paper reports HER2 mutations occur in 2--3%); 64 HER2-mutant patients identified in this institutional series</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling of patient tumors (targeted assays and NGS), literature-cited functional studies and clinical responses to HER2-targeted agents</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper cites literature showing HER2 kinase-domain mutations activate downstream PI3K-AKT and MEK-ERK signaling and are transforming; extracellular mutations shown oncogenic in functional analyses (cited refs).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in females, never-smokers, and adenocarcinoma histology; median age ~62 in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable with HER2-directed therapies (HER2 TKIs such as afatinib, dacomitinib, neratinib, lapatinib; trastuzumab/trastuzumab-containing regimens), but clinical benefit is variable and often limited; chemotherapy (pemetrexed-containing regimens) remains important.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>64 HER2-mutant patients identified at the center (38 patients with metastatic disease analyzed in outcomes)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multiplexed sizing assays for indels (EGFR/ERBB2), Sequenom mass-spectrometry hotspot panel (91 mutations in 8 genes), MSK-IMPACT hybrid-capture NGS (341 genes)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e94.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 YVMA insertion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 p.A775_G776insYVMA (12 base-pair in-frame insertion in exon 20)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent 12 bp in-frame insertion (encoding YVMA) in exon 20 of ERBB2, the most common HER2 mutation subtype in lung adenocarcinoma cohorts and associated with activation of downstream signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 p.A775_G776insYVMA (12 bp exon 20 insertion, 'YVMA')</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame insertion (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK → PI3K-AKT and MEK-ERK pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Among HER2-mutant patients in this series: 24 patients (reported as 63%, 95% CI 46–78%); HER2 mutations overall occur in ~2-3% of lung cancers (see above).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling of clinical tumor specimens; literature-cited functional studies and mouse models (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper states this insertion leads to downstream activation of PI3K-AKT and MEK-ERK signaling (cited functional literature); referenced mouse models (in literature) show HER2 YVMA-driven lung tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Commonly found in female, never-smoker patients with lung adenocarcinoma; in this cohort median overall survival for patients with YVMA was reported separately (1.9 years).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Mixed: some reports of durable responses to afatinib for YVMA cases, whereas a referenced phase II dacomitinib trial reported no responses among 13 identical YVMA cases; overall variable sensitivity to HER2 TKIs and other HER2-directed agents.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Reported in 24 patients in the study's analyzed cohort (paper reports 24/38 metastatic patients had this insertion in the abstract; section details are consistent with majority subtype).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multiplexed sizing assays for insertions/deletions and targeted NGS / hotspot panels as described in Methods</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e94.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 exon 20 insertions (non-YVMA)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 exon 20 in-frame insertions (9-bp, 6-bp, 3-bp variants)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Less-common in-frame insertions in ERBB2 exon 20 (various lengths) observed in lung adenocarcinomas as recurrent activating alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 exon 20 in-frame insertions (examples: 9 base-pair, 6 base-pair, and 3 base-pair insertions reported)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame insertions (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK → PI3K-AKT and MEK-ERK pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>In this series: 34 patients had exon 20 insertions overall (including the 24 YVMA cases); specific 9-bp/6-bp/3-bp counts: 4 (9 bp), 1 (6 bp), 5 (3 bp) reported (cohort denominators reported in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling of tumors (assay panel and NGS) and cited functional literature for kinase-domain insertions</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper groups these with activating kinase-domain mutations; general activation of downstream signaling is cited from literature but specific functional data for each insertion type is not detailed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed in lung adenocarcinoma patients; cohort enriched for female and never-smokers as above.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potentially targetable by HER2-directed agents, but sensitivity appears variable by specific alteration and by agent; clinical outcomes with HER2 TKIs in cohort were generally shorter than chemotherapy for many patients.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Reported collectively in 34 patients in the institutional series (see paper); subset counts provided for specific insertion lengths.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Assays for insertions/deletions (multiplexed sizing), Sequenom hotspot testing, and MSK-IMPACT hybrid-capture NGS</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e94.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 exon 20 point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 exon 20 point substitutions (examples L755F, V777L, D769H)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-base substitutions in the ERBB2 kinase domain detected in lung adenocarcinomas; reported as part of the mutation spectrum though less frequent than exon 20 insertions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 L755F, V777L, D769H (single base substitutions in exon 20)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense substitutions)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>In this study: 4 patients had single base pair substitutions (L755F, V777L, D769H among them) out of the reported HER2-mutant cases; overall HER2 mutations occur in ~2-3% of lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling of clinical tumor specimens (Sequenom/hotspot and NGS); literature-cited functional studies for kinase-domain point mutations generally</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper lists these mutations but does not provide mutation-specific functional data; kinase-domain mutations are cited in the literature as activating/transforming.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Part of HER2-mutant patient group enriched for females and never-smokers; no mutation-specific clinicopathologic distinctions reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Considered potentially targetable by HER2-directed agents, but the paper reports variable responses across HER2 alterations and agents; no mutation-specific treatment conclusions presented.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>4 patients with single base substitutions reported among the institutional HER2-mutant series (total HER2-mutant sample as above).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sequenom mass-spectrometry hotspot testing, multiplexed sizing assays, and MSK-IMPACT NGS</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e94.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 S310F (extracellular)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 p.S310F (extracellular domain point mutation, exon 8)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An extracellular-domain missense mutation in ERBB2 (S310F) identified in lung adenocarcinoma; previously shown in functional analyses to be oncogenic.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 p.S310F (exon 8 extracellular domain point mutation)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense substitution in extracellular domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / receptor tyrosine kinase → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Reported as one of the rarer HER2 mutations in this series (1 patient reported with S310F); HER2 mutations overall ~2-3% in lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling in this clinical series; cited functional studies demonstrating oncogenicity (literature ref cited in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Paper states S310F was previously shown to be oncogenic in functional analysis (cited ref), indicating activating capability despite extracellular location.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed in lung adenocarcinoma; paper does not report unique clinicopathologic features specific to S310F beyond those for HER2-mutant cases.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>As an activating HER2 mutation, may be targetable by HER2-directed agents; clinical response data for S310F specifically not reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>1 patient with S310F reported in this institutional HER2-mutant series (overall cohort sizes as above).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sequenom hotspot testing / MSK-IMPACT NGS / multiplexed assays as used in study</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e94.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e94.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 amplification (distinct)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 (HER2) gene amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Copy-number gain/amplification of ERBB2 is noted as a molecularly distinct event from ERBB2 mutation in lung cancers and represents a separable therapeutic target.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 (HER2) gene amplification (copy number gain)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene amplification / copy number alteration</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature citation within paper (cited reference states amplification and mutation are distinct molecular targets)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Paper notes that HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers (cited literature) but does not provide cohort-level clinical associations for amplification.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Implicates separate therapeutic consideration (amplification may predict benefit from HER2-directed therapies distinct from mutation-driven cases); paper cites literature on distinction but provides no direct amplification-outcome data.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not directly assessed in this study cohort (mentioned via literature); typical detection would be by copy-number assays / FISH / NGS-based copy number, but paper does not detail methods for amplification here.</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.', 'publication_date_yy_mm': '2016-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas <em>(Rating: 2)</em></li>
                <li>Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 <em>(Rating: 2)</em></li>
                <li>HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy <em>(Rating: 2)</em></li>
                <li>Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives <em>(Rating: 2)</em></li>
                <li>HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers <em>(Rating: 2)</em></li>
                <li>Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors <em>(Rating: 2)</em></li>
                <li>Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>